FULL PAPER Multiparametric MRI with diffusion- weighted imaging in predicting response to chemotherapy in cases of osteosarcoma and Ewing’s sarcoma

Objective: To evaluate the multiparametric MRI in predicting chemotherapy response in pathologically proven cases of osteosarcoma and Ewing’s sarcoma. Correlation between the tumor size changes and internal breakdown using RECIST 1.1, modified RECIST, quantitative apparent diffusion coefficient (ADC) and tumor volume as well as dynamic contrast- enhanced MRI (DCE- MRI). The study included 104 patients pathologically proved osteosarcoma (53) and Ewing`s sarcoma (51) underwent MRI examinations; before and after chemotherapy. All patients were assessed using the RECIST 1.1 criteria, m- RECIST, quantitative ADC, and tumor volume evaluation. 21 patients underwent DCE- MRI curve type with quantitative parameters. Correlation between the different evaluations was carried out. Results were correlated with the post- operative pathology in 42 patients who underwent surgery and for statistical evaluation, Those patients were classified into responders ( ≥ 90% necrosis) and non- responders (<90% necrosis). Results: The initial mean ADC of 104 patients of osteosarcoma and Ewing’s sarcoma (0.90 ± 0.29) and (0.71 ± 0.16) respectively, differed significantly from that after treatment (1.62 ± 0.46) and (1.6 ± 0.39) respectively with ( p <0.001).

[1]  L. Fayad,et al.  Review of dynamic contrast‐enhanced MRI: Technical aspects and applications in the musculoskeletal system , 2018, Journal of magnetic resonance imaging : JMRI.

[2]  J. Martín-Broto,et al.  Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS) , 2017, Cancer Chemotherapy and Pharmacology.

[3]  G. Wang,et al.  Diagnostic value of combined diffusion-weighted imaging with dynamic contrast enhancement MRI in differentiating malignant from benign bone lesions. , 2017, Clinical radiology.

[4]  N. Adachi,et al.  Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis. , 2017, Molecular and clinical oncology.

[5]  N. Adachi,et al.  Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis , 2016, Skeletal Radiology.

[6]  Theodoros Soldatos,et al.  Multiparametric Assessment of Treatment Response in High-Grade Soft-Tissue Sarcomas with Anatomic and Functional MR Imaging Sequences. , 2016, Radiology.

[7]  J. Bloem,et al.  Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic r , 2016, European journal of cancer.

[8]  J. Vilanova,et al.  Assessment of Musculoskeletal Malignancies with Functional MR Imaging. , 2016, Magnetic resonance imaging clinics of North America.

[9]  A. Malhotra,et al.  Evaluation of static and dynamic MRI for assessing response of bone sarcomas to preoperative chemotherapy: Correlation with histological necrosis , 2015, Indian Journal of Radiology and Imaging.

[10]  D. Basu,et al.  Role of Dynamic MRI and Clinical Assessment in Predicting Histologic Response to Neoadjuvant Chemotherapy in Bone Sarcomas , 2014, American journal of clinical oncology.

[11]  B. Seddon,et al.  Tumour volume changes following pre-operative radiotherapy in borderline resectable limb and trunk soft tissue sarcoma. , 2014, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[12]  A. Kaya,et al.  Diffusion-weighted Magnetic Resonance Imaging in the Diagnosis of Bone Tumors: Preliminary Results , 2013, Journal of clinical imaging science.

[13]  Fei Yuan,et al.  Noninvasive Assessment of Response to Neoadjuvant Chemotherapy in Osteosarcoma of Long Bones with Diffusion-Weighted Imaging: An Initial In Vivo Study , 2013, PloS one.

[14]  M. Kransdorf,et al.  From the radiologic pathology archives: ewing sarcoma family of tumors: radiologic-pathologic correlation. , 2013, Radiographics : a review publication of the Radiological Society of North America, Inc.

[15]  L. Fayad,et al.  Musculoskeletal tumors: how to use anatomic, functional, and metabolic MR techniques. , 2012, Radiology.

[16]  G. Bollini,et al.  Value of diffusion-weighted images in differentiating mid-course responders to chemotherapy for osteosarcoma compared to the histological response: preliminary results , 2012, Skeletal Radiology.

[17]  F. Costa,et al.  Diffusion-weighted magnetic resonance imaging for the evaluation of musculoskeletal tumors. , 2011, Magnetic resonance imaging clinics of North America.

[18]  Martin O. Leach,et al.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial , 2009, European Radiology.

[19]  Bernd Hamm,et al.  Diffusion‐weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft‐tissue sarcomas , 2008, Journal of magnetic resonance imaging : JMRI.

[20]  Jürgen Griebel,et al.  Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. , 2003, International journal of radiation oncology, biology, physics.

[21]  N. Jaffe,et al.  Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy regional mapping of viable and nonviable tumor , 1985, Cancer.

[22]  A. Degnan,et al.  Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. , 2018, Clinical imaging.